Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Hospira Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (283)
Cancellation by sponsor (53)

Date

2025 (8)
2024 (12)
2023 (7)
2022 (9)
2021 (30)
2020 (31)
2019 (28)
2018 (1)
2017 (5)
2016 (5)
2015 (4)
2014 (7)
2013 (14)
2012 (1)
2011 (10)
2010 (2)
2009 (16)
2008 (23)
2007 (61)
2006 (7)
2005 (23)
2004 (9)
2001 (2)
2000 (2)
1998 (3)
1997 (4)
1996 (1)
1994 (4)
1992 (4)
1991 (3)

Search

Sponsor content

336 result(s) found, displaying 101 to 110

Hospira Epirubicin Hydrochloride Injection, 10 mg/5 mL Vial Cancelled under Section 30(1)(c) of the Act

28 May 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
Fludarabine Phosphate 50 mg/vial for Injection Cancelled under Section 30(1)(c) of the Act

28 May 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
Hospira Fludarabine Phosphate for Injection, USP 50 mg/vial Cancelled under Section 30(1)(c) of the Act

28 May 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
Hospira Cytarabine 100 mg/mL Injection, 2g/20 mL vial Cancelled under Section 30(1)(c) of the Act

28 May 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
Hospira Cytarabine 20 mg/mL Injection 100 mg/5 mL vial Cancelled under Section 30(1)(c) of the Act

28 May 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
DBL cytarabine 500mg/25mL (preserved) injection vial Cancelled under Section 30(1)(c) of the Act

28 May 2020

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
Caldolor® (Ibuprofen) Injection 400 mg/4 mL vial Cancelled under Section 30(1)(c) of the Act

16 December 2019

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
DBL Sodium Bicarbonate Injection BP 8.4%, 8.4 g/100 mL vial Cancelled under Section 30(1)(c) of the Act

16 December 2019

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
Hospira CYTARABINE INJECTION 1g/50mL (USA) Cancelled under Section 30(1)(c) of the Act

16 December 2019

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd
Hospira Cytarabine Injection 500 mg/5 mL vial (CA) Cancelled under Section 30(1)(c) of the Act

16 December 2019

Cancellation by sponsor

Requested by Hospira Australia Pty Ltd

Pages

First page
Previous page
…
Page 7
Page 8
Page 9
Page 10
Current page 11
Page 12
Page 13
Page 14
Page 15
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.